RANITIDINE HYDROCHLORIDE WITH THEIR IN-VITRO AND IN-VIVO PARAMETERS OF GRDDS
Abstract
New histamine H2-receptor antagonist ranitidine lacks the imidazole group observed in cimetidine. Ranitidine suppresses excessive stomach acid secretion in persons 4-10 times more efficiently per weight than cimetidine. In recent years, GRDDSs have soared in popularity as a technique of giving medications orally. Many difficulties, such as poor bioavailability, are addressed by this strategy, which entails retaining the dosage form in the stomach for a long period and releasing the drug slowly. The production of GRDDS makes use of a variety of cutting-edge procedures, such as magnetic field assisted gastro-retention, plug type swelling system, muco-adhesion technique, floating system with or without effervescence. To achieve enhanced gastro-retention and longer drug release, a well-designed in vivo study is important for successful GRDDS development in addition to in vitro characterization. In vivo stomach residency time is commonly measured using gamma scintigraphy and magnetic resonance imaging. Despite the various advantages, the number of GRDDS on the market is constrained by the large subject variability in gastrointestinal physiological condition, effect of meals, and variable rate of stomach emptying time. This article highlights current in-vivo GRDDS research, concentrating on its accomplishments, shortcomings, and the barriers that need to be overcome.
Keywords:GRDDS, H2-receptor antagonist, Ranitidine, Pharmacodynamic
Author(s):Jyoti Singh
Email:jyotisinghsisodia786@gmail.com
DOI:-
Orcid-id:https://orcid.org/0009-0002-8401-1542
